OFFICE/LABORATORY LEASE BETWEEN EMERY STATION OFFICE II, LLC (LANDLORD) AND KYVERNA THERAPEUTICS, INC. (TENANT) 5980 Horton Street Emeryville, CaliforniaWorkletter Agreement • December 13th, 2023 • Kyverna Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Certain identified information has been omitted from this exhibit because it is both (i) not material and brackets (“[…***…]”) in this exhibit.*** PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE This Agreement is based on the model Patent...Patent License Agreement – Exclusive • December 13th, 2023 • Kyverna Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Shipping Information), Appendix G (Example Royalty Report), and Appendix H (Royalty Payment Options).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • December 13th, 2023 • Kyverna Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of November 9, 2021, by and among Kyverna Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
FIRST AMENDMENT (5980 Horton Street, Emeryville, California)First Amendment • December 13th, 2023 • Kyverna Therapeutics, Inc. • Biological products, (no disgnostic substances)
Dear Dominic: On December 9, 2019, you executed an offer letter from Kyverna Therapeutics, Inc. (the “Company”) dated December 8, 2019 (the “Original Offer Letter”). You also entered into an Employee Inventions and Proprietary Information Agreement...Kyverna Therapeutics, Inc. • December 13th, 2023 • Biological products, (no disgnostic substances)
Accordingly, effective as of the start date of the Company’s new CEO (the “Effective Date”), the following terms will apply to your continued employment with the Company:
